Patent ID: 9580503
Date: 2017-02-28
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of treating renal cancer in a subject in need thereof, the method comprising: administering to said subject a therapeutically effective dose of an isolated human antibody or antigen-binding fragment thereof, that specifically binds T cell, immunoglobulin domain and mucin domain 1 (TIM-1), wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain amino acid sequence comprising three complementarity determining regions (CDRs) and a light chain amino acid sequence comprising three CDRs, wherein the three heavy chain CDRs and the three light chain CDRs are selected from the group consisting of: (a) a heavy chain CDR1 comprising the amino acid sequence of residues 45-54 of SEQ ID NO: 50, a heavy chain CDR2 comprising the amino acid sequence of residues 69-85 of SEQ ID NO: 50, a heavy chain CDR3 comprising the amino acid sequence of residues 118-131 of SEQ ID NO: 50, a light chain CDR1 comprising the amino acid sequence of residues 44-60 of SEQ ID NO: 52, a light chain CDR2 comprising the amino acid sequence of residues 76-82 of SEQ ID NO: 52, and a light chain CDR3 comprising the amino acid sequence of residues 115-123 of SEQ ID NO: 52; (b) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 126, a heavy chain CDR2 comprising the amino acid sequence of residues 50-66 of SEQ ID NO: 126, a heavy chain CDR3 comprising the amino acid sequence of residues 99-102 of SEQ ID NO: 126, a light chain CDR1 comprising the amino acid sequence of residues 24-35 of SEQ ID NO: 127, a light chain CDR2 comprising the amino acid sequence of residues 51-57 of SEQ ID NO: 127, and a light chain CDR3 comprising the amino acid sequence of residues 90-99 of SEQ ID NO: 127; (c) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 136, a heavy chain CDR2 comprising the amino acid sequence of residues 50-66 of SEQ ID NO: 136, a heavy chain CDR3 comprising the amino acid sequence of residues 99-112 of SEQ ID NO: 136, a light chain CDR1 comprising the amino acid sequence of residues 24-40 of SEQ ID NO: 137, a light chain CDR2 comprising the amino acid sequence of residues 52-62 of SEQ ID NO: 137, and a light chain CDR3 comprising the amino acid sequence of residues 95-103 of SEQ ID NO: 137; (d) a heavy chain CDR1 comprising the amino acid sequence of residues 26-37 of SEQ ID NO: 130, a heavy chain CDR2 comprising the amino acid sequence of residues 52-67 of SEQ ID NO: 130, a heavy chain CDR3 comprising the amino acid sequence of residues 100-113 of SEQ ID NO: 130, a light chain CDR1 comprising the amino acid sequence of residues 24-34 of SEQ ID NO: 131, a light chain CDR2 comprising the amino acid sequence of residues 50-56 of SEQ ID NO: 131, and a light chain CDR3 comprising the amino acid sequence of residues 89-97 of SEQ ID NO: 131; (e) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 122, a heavy chain CDR2 comprising the amino acid sequence of residues 50-66 of SEQ ID NO: 122, a heavy chain CDR3 comprising the amino acid sequence of residues 99-112 of SEQ ID NO: 122, a light chain CDR1 comprising the amino acid sequence of residues 24-34 of SEQ ID NO: 123, a light chain CDR2 comprising the amino acid sequence of residues 50-56 of SEQ ID NO: 123, and a light chain CDR3 comprising the amino acid sequence of residues 89-97 of SEQ ID NO: 123; (f) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 132, a heavy chain CDR2 comprising the amino acid sequence of residues 50-66 of SEQ ID NO: 132, a heavy chain CDR3 comprising the amino acid sequence of residues 99-112 of SEQ ID NO: 132, a light chain CDR1 comprising the amino acid sequence of residues 24-34 of SEQ ID NO: 133, a light chain CDR2 comprising the amino acid sequence of residues 50-56 of SEQ ID NO: 133, and a light chain CDR3 comprising the amino acid sequence of residues 89-97 of SEQ ID NO: 133; (g) a heavy chain CDR1 comprising the amino acid sequence of residues 29-38 of SEQ ID NO: 128, a heavy chain CDR2 comprising the amino acid sequence of residues 53-69 of SEQ ID NO: 128, a heavy chain CDR3 comprising the amino acid sequence of residues 102-115 of SEQ ID NO: 128, a light chain CDR1 comprising the amino acid sequence of residues 39-55 of SEQ ID NO: 129, a light chain CDR2 comprising the amino acid sequence of residues 71-77 of SEQ ID NO: 129, and a light chain CDR3 comprising the amino acid sequence of residues 110-118 of SEQ ID NO: 129; (h) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 118, a heavy chain CDR2 comprising the amino acid sequence of residues 50-68 of SEQ ID NO: 118, a heavy chain CDR3 comprising the amino acid sequence of residues 101-107 of SEQ ID NO: 118, a light chain CDR1 comprising the amino acid sequence of residues 24-39 of SEQ ID NO: 119, a light chain CDR2 comprising the amino acid sequence of residues 55-61 of SEQ ID NO: 119, and a light chain CDR3 comprising the amino acid sequence of residues 94-102 of SEQ ID NO: 119; (i) a heavy chain CDR1 comprising the amino acid sequence of residues 30-41 of SEQ ID NO: 114, a heavy chain CDR2 comprising the amino acid sequence of residues 56-71 of SEQ ID NO: 114, a heavy chain CDR3 comprising the amino acid sequence of residues 104-113 of SEQ ID NO: 114, a light chain CDR1 comprising the amino acid sequence of residues 39-49 of SEQ ID NO: 115, a light chain CDR2 comprising the amino acid sequence of residues 65-71 of SEQ ID NO: 115, and a light chain CDR3 comprising the amino acid sequence of residues 104-112 of SEQ ID NO: 115; (j) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 124, a heavy chain CDR2 comprising the amino acid sequence of residues 50-68 of SEQ ID NO: 124, a heavy chain CDR3 comprising the amino acid sequence of residues 101-107 of SEQ ID NO: 124, a light chain CDR1 comprising the amino acid sequence of residues 24-39 of SEQ ID NO: 125, a light chain CDR2 comprising the amino acid sequence of residues 55-61 of SEQ ID NO: 125, and a light chain CDR3 comprising the amino acid sequence of residues 94-102 of SEQ ID NO: 125; (k) a heavy chain CDR1 comprising the amino acid sequence of residues 28-37 of SEQ ID NO: 116, a heavy chain CDR2 comprising the amino acid sequence of residues 52-68 of SEQ ID NO: 116, a heavy chain CDR3 comprising the amino acid sequence of residues 101-103 of SEQ ID NO: 116, a light chain CDR1 comprising the amino acid sequence of residues 38-53 of SEQ ID NO: 117, a light chain CDR2 comprising the amino acid sequence of residues 69-75 of SEQ ID NO: 117, and a light chain CDR3 comprising the amino acid sequence of residues 108-116 of SEQ ID NO: 117; and (l) a heavy chain CDR1 comprising the amino acid sequence of residues 26-35 of SEQ ID NO: 120, a heavy chain CDR2 comprising the amino acid sequence of residues 50-66 of SEQ ID NO: 120, a heavy chain CDR3 comprising the amino acid sequence of residues 99-102 of SEQ ID NO: 120, a light chain CDR1 comprising the amino acid sequence of residues 24-39 of SEQ ID NO: 121, a light chain CDR2 comprising the amino acid sequence of residues 55-61 of SEQ ID NO: 121, and a light chain CDR3 comprising the amino acid sequence of residues 94-103 of SEQ ID NO: 121.